Medication info
Trachieduo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Trachieduo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Yellow oval-shaped extended-release film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202400025 · Approved 2024.01.04 · Insurance code 671707380

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine equivalent to a total daily dose of linagliptin 5mg and the patient's current dose of metformin hydrochloride should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be needed to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Special Populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to <45mL/min or estimated glomerular filtration rate (eGFR) decreases to <45mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication helps patients with type 2 diabetes to control their blood sugar levels more effectively. It serves to complement dietary and exercise therapy especially when taken together with linagliptin and metformin. This helps lower blood glucose levels and assist in diabetes management. The effect can be enhanced when used in conjunction with lifestyle modifications. This medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine equivalent to a total daily dose of linagliptin 5mg and the patient's current dose of metformin hydrochloride should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be needed to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Special Populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to <45mL/min or estimated glomerular filtration rate (eGFR) decreases to <45mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication helps regulate blood sugar levels. However, it can rarely cause a serious metabolic complication called lactic acidosis, so caution is necessary. Lactic acidosis occurs when lactate accumulates excessively in the body, requiring immediate treatment; it can be life-threatening in severe cases. This medication should not be used in patients with specific conditions, such as type 1 diabetes, severe renal impairment, liver dysfunction, or in those with acute infections or dehydration. Furthermore, it should not be administered in cases of acute alcohol intoxication or alcoholism. This medication can cause hypoglycemia, so dosage adjustments may be necessary when used in conjunction with other hypoglycemic agents, such as insulin or sulfonylureas. If symptoms such as abdominal pain, muscle weakness, or difficulty breathing occur during treatment, consult a doctor immediately. Regular kidney function tests are important to ensure the medication's safety, and it should not be used if renal function is impaired. Temporary cessation of medication may be required in situations affecting kidney function, such as surgery or radiology tests. Rarely, side effects such as acute pancreatitis or bullous pemphigoid may occur during the use of this medication, and medical personnel should be informed of any suspicious symptoms immediately. Long-term use may lead to vitamin B12 deficiency, so regular monitoring may be needed. The tablets should not be chewed, crushed, or split, and they may pass through the stool intact, which is normal. This medication can interact with other drugs, so be sure to inform your doctor or pharmacist of any other medications you are taking. Pregnant or breastfeeding women should avoid using this medication and consult about safe alternative treatments. Elderly patients should take special care, as impaired kidney function is common, and regular kidney function tests should be conducted. In cases of overdose, the risk of lactic acidosis increases, so immediate treatment at a medical facility is required, and dialysis may be necessary. This medication should be kept out of reach of children and stored away from moisture.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemic state, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigus-like lesions, joint pain associated with severe conditions and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, gallstones, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, gastritis, dizziness, sensory loss, chest discomfort, weakness, nosebleed, oropharyngeal pain, voice disturbances, allergic rhinitis, exercise-induced dyspnea, wet cough, rhinorrhea, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, androgenetic alopecia, hyperhidrosis, dermatitis, anxiety, confused state, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from air and moisture. Additionally, it is important to store the medication at room temperature, between 1 and 30 degrees Celsius, as extremes of temperature may affect its efficacy.

Appearance and packaging

Appearance

Yellow oval-shaped extended-release film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.